ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Missing protein explains link between obesity, diabetes

Fish oil use associated with brain volume preservation

The Brain Boosting and Fatigue Fighting B-12

Genetic basis for distinct type of autism uncovered

Genetic study suggests causal link between vitamin D deficiency and hypertension

Unsuspected aspect of immune regulation revealed: Role of B cells

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

Explaining 'Healthy' Obesity

Sinus Congestion and Sinusitis, Healing Naturally

In the gut, immunity is a two-way street

 
Print Page
Email Article

Trial of Eszopiclone (Lunesta®) for Insomnia & Other FM Symptoms

  [ 559 votes ]   [ Discuss This Article ]
By Editor • www.ProHealth.com • February 2, 2007


A Phase IV study at Robert Wood Johnson Medical School in Piscataway, New Jersey, is testing the sleep drug eszopiclone (Lunesta®) for the treatment of insomnia and other symptoms of Fibromyalgia. The trial, sponsored by Sepracor, Inc., is recruiting Fibromyalgia patients of both sexes between the ages of 18 and 64.

Study Purpose and Hypothesis
“Although the pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but has not been studied in the treatment of FMS. The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of Fibromyalgia (FMS) in FMS patients. Participants will be randomly selected to receive eszopiclone or placebo. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo (fake dose).

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: “Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia” (ClinicalTrials.com number NCT00392041)

Primary Outcome to Be Measured
n Total sleep time (TST) as recorded in patient diaries

Secondary Outcomes to Be Measured
n Wake time after sleep onset (WASO)
n Sleep quality
n Clinician-rated overall severity of Fibromyalgia
n Fibromyalgia Impact Questionnaire

Requirements for Inclusion:
n Male or female, age 18 through 64.
n Meets ACR criteria for FMS, as determined by rheumatological examination and a medical history review.
n Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as well as clinically significant daytime distress or impairment during the 1 week self assessment prior to baseline.
n Has completed 8th grade and is fluent in English.
n If a female of child bearing potential, the patient must be non-pregnant and either post-menopausal or using an approved birth control method. Acceptable birth control methods include: history of tubal ligation, having a male partner who is sterile, IUDs, birth control pills or other hormonal birth control methods (e.g., birth control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).
n Antidepressant medication will be allowed if the patient has been on a stable dose for at least one month.

Exclusion Criteria:
n Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or endocrine-related arthropathy.
n Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior disorder.
n Any current, clinically significant medical condition.
n Pregnancy.
n Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain syndrome, or psychoactive substance abuse or dependence.
n Any current psychiatric disorder that would interfere with study participation (investigator judgment).
n Active suicidal ideation.
n Plans to engage in additional psychotherapy during the study.
n Concurrent use of benzodiazepines after 6pm or as a sleep aid.
n Concurrent use of any other sleep aid.
n Concurrent use of analgesics other than acetaminophen or non-steroidal anti-inflammatory medication.
n Concurrent use of any medication that has not been stabilized for at least 1 month prior to screening.

Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00392041

Department of Psychiatry, University of Medicine and Dentistry New Jersey
(UMDNJ)-Robert Wood Johnson Medical School, Piscataway, New Jersey

Prinical Investigator Lesley A. Allen, PhD 732-235-4412
allenla@umdnj.edu Jade Tiu, B.A. 732-235-3378
tiuje@umdnj.edu

Health Authority: United States Institutional Review Board





Discuss This Article Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Sweet Tips for Fibromyalgia Success
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing